We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Gilead Sciences (GILD - Free Report) shares have continued to rise after beating on both its top and bottom lines in October. GILD stock is up roughly 20% since its Q3 release, with the stock sporting a Zacks Rank #2 (Buy).
There may be more upside ahead for Gilead. Let’s take a look at what could continue propelling GILD stock.
Medical Pioneer
Gilead Sciences is well known for its ground-breaking treatments in human immunodeficiency virus (HIV), liver diseases, hematology/oncology diseases, and inflammation/respiratory diseases. GILD’s portfolio also includes drugs for Hepatitis C.
The company also illustrated its fast ability to construct prevention efforts during the pandemic with its FDA-approved Covid-19 treatment remdesivir. GILD’s Q3 earnings crushed the Zacks consensus estimate by 32% at $1.90 per share although this was down 28% YoY. Sales of Veklury, the brand name for remdesivir were up 11% from Q3 2021 at $6.05 billion.
The YoY earnings decrease was primarily driven by the acquisition of MiroBio. The $405 million cash deal will provide Gilead with MiroBio’s proprietary discovery platform and its entire portfolio of immune inhibitory receptor agonists. This is expected to complement Gilead’s inflammation research and development strategy which is the next product area the company aspires to advance in.
For now, the company’s profitability continues to lie within its growing HIV sales. HIV product sales for Q3 were up 7% YoY at $4.48 billion. Overall, sales beat top line expectations by 15% at $7.04 billion. This was a 5% decrease from Q3 2021 primarily driven by lower Veklury sales as we move further into a post-pandemic world.
Still, Biktarvy, a medication used for the treatment of HIV/AIDS, saw sales increase 22% YoY to $2.8 billion. Another growth highlight was the 79% increase in oncology sales to $578 million.
Image Source: Zacks Investment Research
This continued growth is impressive and could help GILD stock continue to outperform the broader market despite an economic downturn as consumers will spare no expense when it comes to essential medication.
Outlook
Year over year, GILD earnings are now expected to decline -2% to $7.09 per share. However, earnings estimates have significantly gone up from $6.61 a share 90 days ago. FY23 earnings are expected to drop another -4% to $6.79 per share but earnings estimate revisions for next year have also gone up during the quarter.
Sales are projected to be down -3% this year and another -4% in FY23 to $25.34 billion. Top line estimates have also trended higher since GILD’s Q3 report.
Performance & Valuation
GILD is up +17% YTD to largely outperform the S&P 500’s -18% and its peer group’s -28% with notable companies such as Amgen (AMGN - Free Report) and Moderna (MRNA - Free Report) . Even better, GILD’s total return is +22% YTD when adding in its strong dividend.
Image Source: Zacks Investment Research
Gilead Sciences has continued to be a pioneer and industry leader. Over the last decade, GILD’s total return is +188% to beat its peer group’s +137%.
Trading around $85 per share, GILD trades at 11.8X forward earnings. This is lower than the industry average P/E of 21.1X. Despite GILD’s impressive rally over the last few weeks, the stock still trades at a discount to its decade-high of 38.4X and is not far from the median of 9.8X.
Image Source: Zacks Investment Research
Bottom Line
On top of GILD’s solid 3.46% annual dividend yield at $2.92 per share, the stock is seeing rising earnings estimate revisions. This makes Gilead Sciences very intriguing for investors, as GILD stock has continued to outperform the broader market and recently reached new highs. This could continue as GILD’s Biomedical and Genetics Industry is currently in the top 21% of over 250 Zacks Industries and the stock has an overall “A” VGM grade.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Buy this Medical Sector Pioneer Stock
Gilead Sciences (GILD - Free Report) shares have continued to rise after beating on both its top and bottom lines in October. GILD stock is up roughly 20% since its Q3 release, with the stock sporting a Zacks Rank #2 (Buy).
There may be more upside ahead for Gilead. Let’s take a look at what could continue propelling GILD stock.
Medical Pioneer
Gilead Sciences is well known for its ground-breaking treatments in human immunodeficiency virus (HIV), liver diseases, hematology/oncology diseases, and inflammation/respiratory diseases. GILD’s portfolio also includes drugs for Hepatitis C.
The company also illustrated its fast ability to construct prevention efforts during the pandemic with its FDA-approved Covid-19 treatment remdesivir. GILD’s Q3 earnings crushed the Zacks consensus estimate by 32% at $1.90 per share although this was down 28% YoY. Sales of Veklury, the brand name for remdesivir were up 11% from Q3 2021 at $6.05 billion.
The YoY earnings decrease was primarily driven by the acquisition of MiroBio. The $405 million cash deal will provide Gilead with MiroBio’s proprietary discovery platform and its entire portfolio of immune inhibitory receptor agonists. This is expected to complement Gilead’s inflammation research and development strategy which is the next product area the company aspires to advance in.
For now, the company’s profitability continues to lie within its growing HIV sales. HIV product sales for Q3 were up 7% YoY at $4.48 billion. Overall, sales beat top line expectations by 15% at $7.04 billion. This was a 5% decrease from Q3 2021 primarily driven by lower Veklury sales as we move further into a post-pandemic world.
Still, Biktarvy, a medication used for the treatment of HIV/AIDS, saw sales increase 22% YoY to $2.8 billion. Another growth highlight was the 79% increase in oncology sales to $578 million.
Image Source: Zacks Investment Research
This continued growth is impressive and could help GILD stock continue to outperform the broader market despite an economic downturn as consumers will spare no expense when it comes to essential medication.
Outlook
Year over year, GILD earnings are now expected to decline -2% to $7.09 per share. However, earnings estimates have significantly gone up from $6.61 a share 90 days ago. FY23 earnings are expected to drop another -4% to $6.79 per share but earnings estimate revisions for next year have also gone up during the quarter.
Sales are projected to be down -3% this year and another -4% in FY23 to $25.34 billion. Top line estimates have also trended higher since GILD’s Q3 report.
Performance & Valuation
GILD is up +17% YTD to largely outperform the S&P 500’s -18% and its peer group’s -28% with notable companies such as Amgen (AMGN - Free Report) and Moderna (MRNA - Free Report) . Even better, GILD’s total return is +22% YTD when adding in its strong dividend.
Image Source: Zacks Investment Research
Gilead Sciences has continued to be a pioneer and industry leader. Over the last decade, GILD’s total return is +188% to beat its peer group’s +137%.
Trading around $85 per share, GILD trades at 11.8X forward earnings. This is lower than the industry average P/E of 21.1X. Despite GILD’s impressive rally over the last few weeks, the stock still trades at a discount to its decade-high of 38.4X and is not far from the median of 9.8X.
Image Source: Zacks Investment Research
Bottom Line
On top of GILD’s solid 3.46% annual dividend yield at $2.92 per share, the stock is seeing rising earnings estimate revisions. This makes Gilead Sciences very intriguing for investors, as GILD stock has continued to outperform the broader market and recently reached new highs. This could continue as GILD’s Biomedical and Genetics Industry is currently in the top 21% of over 250 Zacks Industries and the stock has an overall “A” VGM grade.